Consolidated Investment Group’s VanEck Biotech ETF BBH Stock Holding History

Consolidated Investment Group’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,000	Closed	-$787K	–	66
2025 Q1	$787K	Sell	5,000 -11,200	-69%	-$1.82M	0.12%	66
2024 Q4	$2.54M	Hold	16,200	–	–	0.36%	49
2024 Q3	$2.87M	Hold	16,200	–	–	0.43%	47
2024 Q2	$2.73M	Sell	16,200 -13,500	-45%	-$2.21M	0.42%	48
2024 Q1	$4.94M	Hold	29,700	–	–	0.8%	33
2023 Q4	$4.91M	Hold	29,700	–	–	0.87%	30
2023 Q3	$4.63M	Hold	29,700	–	–	0.89%	30
2023 Q2	$4.63M	Hold	29,700	–	–	0.83%	31
2023 Q1	$4.81M	Buy	29,700 +2,800	+10%	+$453K	0.94%	27
2022 Q4	$4.3M	Buy	26,900 +4,700	+21%	+$744K	0.92%	29
2022 Q3	$3.13M	Buy	22,200 +1,500	+7%	+$227K	0.68%	43
2022 Q2	$3.02M	Buy	20,700 +2,700	+15%	+$402K	0.58%	51
2022 Q1	$2.92M	Buy	+18,000	New	+$2.92M	0.48%	55

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Consolidated Investment Group's BBH Position: Q2 2025 in Review

Consolidated Investment Group sold out of VanEck Biotech ETF (BBH) in Q2 2025, closing a stake of 5,000 shares — an estimated $787K sold.

Consolidated Investment Group first reported a position in BBH in Q1 2022 and held it in 13 quarters. The position peaked at $4.94M in Q1 2024. 98 funds tracked by Wall St. Rank hold BBH as of Q2 2025.

Consolidated Investment Group reported no remaining VanEck Biotech ETF position as of Q2 2025 after selling out during the quarter.
Consolidated Investment Group sold 5,000 VanEck Biotech ETF shares in Q2 2025, an estimated $787K.
Consolidated Investment Group first reported a position in VanEck Biotech ETF in Q1 2022 and held it in 13 quarters.
Consolidated Investment Group's VanEck Biotech ETF position peaked at $4.94M in Q1 2024.
98 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2025.

Based on Consolidated Investment Group's 13F filing for Q2 2025, filed 21 Jul 2025.